Background: C-Myc is a short-lived oncoprotein that is destroyed by ubiquitin-mediated proteolysis. Dysregulated accumulation of c-Myc commonly occurs in human cancers. Some of those cases with the dysregulated c-Myc protein accumulation are attributed to gene amplification or increased mRNA expression. However, the abnormal accumulation of c-Myc protein is also a common finding in human cancers with normal copy number and transcription level of c-Myc gene. It seems that the mechanistic dysregulation in the control of c-Myc protein stabilization is another important hallmark associated with c-Myc accumulation in cancer cells. Here we report a novel mechanistic pathway through which DNAdependent protein kinase catalytic subunit (DNA-PKcs) modulates the stability of c-Myc protein.
Background
The c-Myc oncoprotein is a short-lived basic helix-loophelix leucine-zipper transcription factor that, together with its dimerization partner Max, binds to specific E-box sequences and is responsible for controlling a set of genes whose functions impinge directly upon the machinery of cell growth and proliferation [1, 2] . C-myc has the transforming capacity, even the activation of the c-Myc gene alone can lead to the formation of liver cancers and inactivation of the c-Myc is sufficient to induce sustained regression of invasive liver cancers [3] . Dysregulated accumulation of c-Myc oncoprotein commonly occurs in various human cancers (30-50%) [4] [5] [6] [7] [8] [9] , and in most cases is associated with disease progression.
Proteolysis of c-Myc protein within minutes of its synthesis occurs through the ubiquitin-proteasome pathway [10] , which involves the F box protein and the ubiquitin ligase components, Skp2 and Fbw7 [11] [12] [13] [14] [15] . The c-Myc transactivation domain (TAD), spanning amino acids , contains the sequence PTPPLSP (residues 57-63), within which both T58 and S62 are phosphorylated. The critical phosphorylation event of T58 and S62 determines the protein half life [16] . The phosphorylation of S62 mediated by the Ras/MEK/ERK kinase pathway, is believed to be a prerequisite for the phosphorylation of T58 regulated through the phosphatidylinositol 3-kinase/ Akt (PKB)/glycogen synthase kinase 3 (GSK3) pro-survival pathway [7, 17, 18] . Phosphorylation of c-Myc on T58 by GSK3 regulates the binding of Fbw7, which in turn triggers c-Myc ubiquitination and degradation [15] .
Mechanisms for the dysregulated accumulation of c-Myc protein in cancers, as well as the means by which c-Myc stimulates cell proliferation and transformation, have received much attention. Indeed, a number of studies demonstrated that T58 mutation occurred in some cancers, which resulted in decreased ubiquitination and proteolysis of c-Myc [17] [18] [19] . However, the abnormal accumulation of c-Myc protein is also a common finding in human cancers with intact and normal copy or expression levels of the c-Myc gene, suggesting the mechanistic dysregulation in the control of c-Myc protein stabilization in human cancers.
DNA-dependent protein kinase catalytic subunit (DNAPKcs) is a member of a sub-family of proteins containing a phosphoinositol (PI) 3-kinase domain with the activity of a serine/threonine protein kinase [20, 21] . It is well known that DNA-PKcs is required for the non-homologous end joining (NHEJ) pathway of DNA double-strand breaks, V (D) J recombination of immunoglobulin genes and T cell receptor genes [20] , and telomere length maintenance [22, 23] . However, overexpression of DNA-PKcs has recently been unveiled in various human cancers [24] [25] [26] [27] [28] [29] [30] , and its expression level was also reported to correlate with the development of productive tissues or the differentiation and proliferation status of some cell types [31] [32] [33] [34] . It is still unclear what the biological significance is for this overexpressed DNA-PKcs in human cancers. Recently we have reported that silencing of DNA-PKcs mediated by specific siRNA molecules led to strongly decreased c-Myc protein level without changing c-myc mRNA expression [35] , and increased expression of some of the c-Myc repressing genes, e.g. p21, p27 and NDRG1 [36] . In this study, we sought to determine the effect of DNA-PKcs on regulating c-Myc protein stability and focused on the involvement of Akt and GSK3 in its mechanistic pathway using the cell model with siRNA-silenced DNA-PKcs, DNA-PKcs deficient cells. Moreover, we have confirmed the effect of DNA-PKcs on regulating c-Myc stability in an overexpressed DNA-PKcs cell model, generated by subchronically exposing normal human liver L02 cells to very low dose of carcinogen 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD).
Materials and methods
Cell culture and siRNA transfection HeLa, HeLa-NC, HeLa-H1, HepG2, HepG2-NC, HepG2-H1, HepG2-H3, M059K (DNA-PKcs efficient human glioma cells), M059J (DNA-PKcs deficient human glioma cells), normal human liver L02 cells, ATM-deficient AT5BIVA, and human normal foreskin fibroblast HFC cells were maintained in Dulbecco modified Eagle medium (DMEM) containing 10% fatal bovine serum, 100 U/ml of penicillin and 100 μg/ml of streptomycin in a humidified chamber at 37°C in 5% CO 2 . M059K and M059J cell lines were kindly provided by Dr David Chen from the Department of Radiation Oncology, UT Southwestern Medical Center. HeLa-H1, and HeLa-NC were generated from HeLa cells, and HepG2-H1, HepG2-H3, HepG2-NC were generated from HepG2 cells, by stably transfecting with specific siRNA constructs targeting the DNA-PKcs catalytic motif (nucleotides 11637~11655, H1) or translation initiation region (nucleotides 354~372, H3) and a control construct (NC), respectively [35] .
For experiments in which DNA-PKcs, GSK3α or GSK3β was knock-down transiently, the siRNA molecules were synthesized and purified by Cenechem company (Shanghai, China), including DNA-PKcs specific siRNA (5'-GGGCGCUAAUCGUACUGAAdtdt-3'), GSK3α specific siRNA (sense strand: 5'-CAUUCUCAU CCCUCCUCACdtdt-3'), GSK3β specific siRNA (sense strand: 5'-GAGCAAAUCAGAGAAAUGAdtdt-3'), and the non-specific control siRNA (sense strand: 5'-UUCUCCGAACGUGUCACGUdtdt-3'). For siRNA transfection, 1 × 10 5 cells were plated in each well of 6-well culture plate, 24 h later 30 μl of Lipofectamine 2000 reagent (Invitrogen, Caris-bad, CA) was added into 1.5 ml DMEM without antibiotics and serum and incubated at room temperature for 5 min (solution A). A certain amount of siRNA was added into 1.5 ml DMEM without antibiotics and serum (solution B). Solution A and solution B were mixed and incubated at room temperature for 20 min. The medium in the cell culture was removed, and then 0.5 ml of Lipofectamine 2000-siRNA mixture and 1.5 ml of fresh DMEM without antibiotics were added to each culture well and gently mixed. After 48 hours of incubation, the cells were harvested for immunoblotting analysis. 
Antibodies

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) treatment
Normal human liver L02 cells were exposed to 0.01, 0.1, or 1.0 pM TCDD in the growth medium for 48 hours or 2 or 4 weeks. During the period of TCDD sub-chronic treatment, cells were subcultured for each 3-4 days. After ending of TCDD exposure, cells were subjected to growth curve and immunoblotting analyses under normal culture conditions. Cell growth and radiosensitive analyses 5×10 3 cells per well were seeded in 24-well culture plates The cell numbers from three wells were counted every day after plating for each group. Three independent experiments were performed, and the means were used to depict the growth curve.
In the radiosensitive experiment, cells were trypsinized, counted, and diluted to certain concentrations. Cell suspensions were irradiated immediately at room temperature using a 60 Co γ-ray source at a dose rate of 2 Gy/min. Corresponding controls were sham irradiated. A colonyforming assay was performed immediately after irradiation by plating an appropriate number of cells (3 × 10 2 to 1 × 10 4 ) into 60 mm diameter Petri dishes, in triplicate. After two weeks in culture, cells were fixed with methanol, stained with Giemsa solution, and colonies consisting of more than 50 cells were counted. After correction with plating cell numbers, the data of survival colonies were used to plot survival curves.
Immunoblotting analysis and coimmunoprecipitation (CoIP)
The cells were harvested and washed twice in ice-cold phosphate buffered saline. Cell pellets were treated with lysis buffer (50 mmol/L Tris-HCL, pH 7.5, 1% Noridet P40, 0.5% Sodium deoxycholate, 150 mmol/L NaCl, 1 piece of protease inhibitor cocktail tablet in 50 ml solution), and the total protein was isolated. Protein (50 μg) was resolved on SDS/PAGE (8%), and then transferred onto the polyvinylidene fluoride (PVDF) membrane for immunoblotting detection.
In the CoIP experiment, HeLa-H1 and HeLa-NC cells were treated with 20 μM proteasome inhibitor MG132 (Z-LeuLeu-Leu-al) (Sigma, Saint Louis, MO) for 2 h, or 40 mM GSK3 β inhibitor LiCl (ACROS, NJ) or 40 mM KCl (control) for 45 min before cell lysis. Coimmunoprecipitation was performed by using the Immunoprecipitation Kit (Protein A/G, Roche Molecular Biochemicals) according to the manufacturer's instructions. Briefly, cells were washed twice with ice-cold PBS and collected by centrifugation. The cell pellets were resuspended in pre-chilled lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxychoolate and certain amount of complete tablet provided by the Kit) and homogenized. The supernatants were collected by centrifugation at 12 000 × g for 10 min at 4°C to remove debris, and then subjected to immunoprecipitation. After precleared with protein A/G-agarose, the supernatants were reacted for 3 h with 2 μg of anti-c-Myc antibody at 4°C followed by overnight incubation with protein A/G-agarose at 4°C. The immunoprecipitates were collected by centrifugation, and washed twice with washing buffer 1 (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 1% Nonidet P40 and 0.05% sodium deoxychoolate), and one time with washing buffer 2 (10 mM Tris-HCl, pH 7.5, 0.1% Nonidet P40 and 0.05% sodium deoxychoolate). The immunoprecipitates were denatured by heating to 100°C for 3 min in gel-loading buffer and centrifuged at 12 000 × g for 20 s to remove the protein A/G-agarose. The denatured proteins were resolved by 8% SDS-PAGE and subjected to immunoblotting analysis with the anti-ubiquitin antibody.
Determination of c-Myc protein stability
HeLa-H1 and HeLa-NC cells were pretreated with 20 μM MG132 (Sigma, Saint Louis, MO) for 2 h to accumulate protein, then washed with cold-PBS three times to remove the MG132, followed by treatment with 40 μg/ml cycloheximide (CHX) (Sigma, Saint Louis, MO) at 37°C to block novel protein synthesis. The cells were harvested at the given times after CHX treatment, and subjected to immunoblotting analysis with the anti-c-Myc antibody.
Results
DNA-PKcs modulates c-Myc protein expression and cell proliferation
We have firstly generated a number of cell models, including HeLa-H1, HepG2-H1, HepG2-H3, by silencing DNAPKcs in human cervix cancer HeLa cells or liver cancer HepG2 cells respectively, with specific siRNA molecules targeting different position of DNA-PKcs sequence. The results indicated that siRNA-mediated silencing of DNAPKcs led to stable downregulation of c-Myc protein, and even after 35 passages of subculture, the DNA-PKcs silenced HeLa-H1 cells expresses a lower level of c-Myc protein (Fig. 1A ). Here we further shows that silencing of DNA-PKcs in HepG2 cells by siRNA strategy also leads to a significant depression of c-Myc oncoprotein (Fig. 1B) . Therefore, we compared the c-Myc protein levels between these two cell lines and found that c-Myc level in M059J cells which lack DNA-PKcs was significantly lower than in M059K cells (Fig. 1C) .
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a chemical carcinogen. We found that sub-chronic exposure of normal human liver cells L02 with 0.01 -1.0 pM low dose of TCDD for 2 or 4 weeks dramatically increased DNAPKcs expression. Interestingly, c-Myc protein level was concurrently augmented (Fig. 1D) . We then asked whether depressing DNA-PKcs by siRNA strategy could alter c-Myc protein expression in this TCDD-treated L02 cells model. As shown in Fig. 1E , re-depressing DNA-PKcs by transfecting DNA-PKcs specific siRNA vector into L02/ TCDD-H1 cells downregulated c-Myc protein, as compared with the control L02/TCDD-NC cells which were transected with the control non-specific siRNA vector. It has been demonstrated previously that DNA-PKcs deficiency causes down-regulation of ATM, another member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family [37] . In order to investigate whether the involvement of DNA-PK in regulating c-Myc expression was due to further inhibition of ATM, we compared the cMyc protein levels in ATM-deficient AT5BIVA cells and in normal HFC fibroblasts. As shown in We then investigated whether the alteration of DNA-PKcs expression affects cell proliferation. The clonogenic survival assay showed that siRNA-mediated depression of DNA-PKcs strikingly sensitized HepG2-H1 cells to ionizing radiation (Fig. 2A) . The killing effect of 2Gy irradiation was ~12 times higher on HepG2-H1 cells than on control HepG2-NC cells. Importantly, the growth curve analysis demonstrated that silencing DNA-PKcs decreased the proliferation activity of HepG2 cells (Fig. 2B) as well as HeLa cells (data not shown). It is well documented that exposure to some chemical toxins at very low doses can induce a stimulating effect (hormesis) on cell growth [38, 39] . We demonstrated here that sub-chronic exposure to 0.01 -0.1 pM of TCDD for 2 or 4 weeks drove human liver cells L02 to proliferate a great deal faster (Fig. 2C) . The colony formation assay also showed that the colony focus size of low dose TCDD-treated cells was larger than that of control cells under the same culture conditions (Fig. 2D) . The plating efficiency of TCDD-treated cells was also significantly increased as compared with control cells (Fig. 2D) , while more than 1 pM concentration of TCDD exhibits a depression effect on cell proliferation (data not shown). Moreover, re-depression of DNA-PKcs in TCDDtreated L02 cells by specific-siRNA molecules not only downregulates c-Myc protein (Fig. 1E) , but also re-modulates the proliferation rate to control levels (Fig. 2E,F) .
DNA-PKcs affects ubiquitination and stability of c-Myc protein
To investigate the stability of c-Myc protein, the half-life time of c-Myc was analyzed by measuring c-Myc protein level alteration after blocking protein synthesis with cycloheximide (CHX). We have compared the c-Myc protein levels between DNA-PKcs-depressed cells and the control cells at 0, 30, 45 and 60 min after CHX treatment.
In control HeLa-NC cells, c-Myc protein level decreased only after CHX treatment for more than 60 min. In contrast, c-Myc protein level decreased about 50% at 30 min after CHX treatment in DNA-PKcs silenced cells (HeLa-H1 and HeLa-H3) (Fig. 3A &3B) . We next detected c-Myc ubiquitination, and found that silencing of DNA-PKcs in HeLa-H1 cells promotes the ubiquitination of c-Myc protein (Fig. 3C) . Treatment with LiCl, an inhibitor of GSK3 kinase, impedes c-Myc ubiquitination. This result makes it likely that the downregulation of c-Myc protein by silencing DNA-PKcs is associated with the augmentation of cMyc ubiquitination.
GSK3 activity is necessary for the regulation of DNA-PKcs on c-Myc protein stability
The proteasome inhibitor MG132 remarkably increases cMyc protein level in DNA-PKcs silenced HeLa-H1 cells (Fig. 4A) . Moreover, the GSK kinase inhibitor LiCl can also recover c-Myc protein levels in HeLa-H1 cells (Fig.  4B) . Phosphorylation of c-Myc on T58, which is catalyzed by GSK3 β kinase, is necessary for activating the ubiquitin/ proteasome pathway to destroy c-Myc protein. Although total c-Myc levels in HeLa-H1 cells is lower than that in HeLa-NC cells, the base level of phosphorylated c-Myc protein in HeLa-H1 cells is higher than that in HeLa-NC cells (Fig. 4C) . The accumulated c-Myc protein in MG132-treated HeLa-H1 cells exhibits a higher phosphorylation level as compared to HeLa-NC cells. Inhibition of GSK3 activity by LiCl dramatically decreases the level of phosphorylated c-Myc protein, but increases the accumulation of c-Myc protein in HeLa-H1 cells (Fig. 4C ). In addition, the level of c-Myc protein is increased by siRNA-mediated depression of GSK3 α or β (Fig. 4D) . These results demonstrate that CSK3 plays an important role in c-Myc stabilization modulated by DNA-PKcs.
Effects of DNA-PKcs expression status on cell proliferation and radiosensitivity (Fig. 5A &5B) . Consequently, the phosphorylation level of GSK3 β, a substrate of activated Akt, is simultaneously decreased in the cells lacking DNA-PKcs. Conversely, the phosphorylation of Akt and GSK3 β in normal liver L02 cells is augmented, along with the increasing of DNA-PKcs and c-Myc proteins, as the consequence of subchronic exposure with a low dose of TCDD (Fig. 5C &5D) . We then investigated that whether re-depression of TCDD-augmented DNA-PKcs expression in L02 cells affects the phosphorylation of Akt. We found that transfection with DNA-PKcs specific siRNA not only downregulated the TCDD-augmented DNA-PKcs and c-Myc expression in L02 cells, but also led to a decrease in the phosphorylation of Akt and GSK3 β (Fig. 5E ). Importantly, the increased proliferation activity by a low dose of TCDD exposure was also reversed to the level of control cells (Fig. 2E) . These results indicated that Akt/GSK3 signaling is involved in the pathway through which DNA-PKcs modulates c-Myc stability. 
DNA-PKcs regulates c-Myc stability
Discussion
C-Myc is intimately involved in cell proliferation [1, 2] , carcinogenesis [3] , tumor progression [40, 41] , angiogenesis [42] and metastasis [43] . Dysregulated accumulation of c-Myc protein is often observed in a variety of human cancers [4] [5] [6] [7] [8] [9] . This abnormal accumulation of c-Myc in human cancers can be attributed to multiple causes, for instance, gene translocation and amplification [2, 4, 40, 41, 43, 44] , gene mutations on hot spots, e.g., Thr58 which abolishes c-Myc phosphorylation and results in decreased ubiquitination and proteasome-mediated degradation of c-Myc [7, 18, 19] , and dysregulation of the mechanistic signaling pathway controlling c-Myc stability. In the present study, we highlighted the overexpression of DNA-PKcs and its role in controlling the stability of the oncoprotein c-Myc. Our study demonstrates that DNAPKcs expression status in cells is closely associated with cMyc protein levels.
Recently, overexpression of DNA-PKcs was reported in various human tumors [24] [25] [26] [27] [28] [29] [30] 45] . For example, Hosoi et al. have detected the expression of DNA-PK in tumor tissues and adjacent normal tissues of 12 colorectal cancers, and found that the activity and expression level of DNAPKcs were significantly higher in tumor tissues than in normal tissues [24] . Um et al. have revealed increased protein level and activity of DNA-PKcs in the metastatic cancer cell lines as compared with their parental cells, and suggested that the activities of DNA-PK as well as EGFR are associated with the metastatic phenotype [45] . We have assessed DNA-PKcs in 47 cases of liver neoplasm by immunohistochemistry, and found a wide variation in the expression levels of DNA-PKcs among different types of liver neoplastic tissues. The highest expression was detected in hepatocellular carcinoma, followed by cholangioadeno carcinoma and biliary cystadeno-carcinoma. Relatively weak expression was detected in papillary adenoma cases, but clearly increased expression was observed in cases of papillary adenoma with hyperplasia or infiltration. However, very weak immunohistochemical staining was detected in the adjacent normal tissues [29] . It is believed that a suitable base level of DNA-PKcs in cells is necessary for maintaining the genomic stability via its role in DNA repair. However, the biological significance of overexpressed DNA-PKcs in cancer cells, besides its potential effect of increasing resistance of cancer cells to radiotherapy or chemotherapy, has attracted our attention. Our results indicate that silencing DNA-PKcs of HeLa cells causes not only an increased sensitivity to ionizing radiation ( Fig. 2A) , but also a decrease in proliferation (Fig. 2B ). More interestingly, the increased proliferation of normal human liver L02 cells induced by sub-chronically exposing to low dose of carcinogen TCDD is associated with the overexpression of DNA-PKcs induced by TCDD (Fig. 2C,D) . These results suggest that overexpressed DNA-PKcs plays a role in promoting cell proliferation and even has transforming potential. We have previously reported that silencing DNA-PKcs alters the expression of a set of genes functionally related to proliferation and differentiation, some of which are c-Myc target genes, e.g. p21, p27, NDRG1 [36] . Moreover, siRNA-medicated silencing of DNA-PKcs results in downregulation of c-Myc protein in HeLa cells [35] . Here we DNA-PKcs controls phophsporylation of Akt and GSK3 β further demonstrated that c-Myc protein levels in malignant glioma M059J cells lacking DNA-PKcs is much lower than that in M059K cells expressing DNA-PKcs. In addition, overexpressing DNA-PKcs in normal liver L02 cells by sub-chronic exposure to a low dose of TCDD simultaneously leads to an increased c-Myc level. This increased c-Myc level was re-downregulated along with the depression of DNA-PKcs mediated by siRNA strategy. Therefore, we offered evidence suggesting a novel biological role for DNA-PKcs, which is potentially associated with cell proliferation and transformation through controlling c-Myc protein levels, beyond its well-defined function as a component involved in DNA double-strand break repair and V(D)J recombination.
Silencing of DNA-PKcs does not alter the level of c-Myc mRNA in the cells [35] . Therefore, we suggest that DNAPKcs regulates cellular c-Myc protein levels possibly by affecting the stabilization of c-Myc protein. Phosphorylation of c-Myc protein on Thr58 and Ser62 is essential for the ubiquitin-proteasome pathway of c-Myc destruction. Phosphorylation on Thr58 by GSK3 regulates the binding of Fbw7 to c-Myc, triggering c-Myc ubiquitination and destruction [15] . Our data show that silencing DNA-PKcs leads to increased ubiquitination and decreased half-life of c-Myc protein (Fig. 3) . The phosphorylation of c-Myc on Thr58 was also increased (Fig. 4C ). These data suggest that DNA-PKcs does regulate the stabilization of c-Myc protein by affecting its phosphorylation on Thr58 and ubiquitination.
DNA-PKcs was previously reported to phosphorylate Akt on Ser473 [46] , while Akt phosphorylates and inactivates GSK3 β [47] . It is likely that DNA-PKcs regulates c-Myc stability via phosphorylation of Akt, which in turn inactivates GSK3 β, resulting in stabilization of c-Myc. Therefore, we have further analyzed the possible link between DNA-PKcs and GSK3 β/c-Myc by investigating the role of Akt. Here we observed that silencing DNA-PKcs or DNAPKcs deficiency caused deceased phosphorylation of Akt on Ser473 as well as GSK3 β (Fig. 5A&5B) . Inhibition of GSK3 β by its inhibitor LiCl or specific siRNA rescued the downregulated c-Myc protein mediated by silencing DNA-PKcs (Fig. 4B &4D) . As indicated above, we have established a cell model with an increased DNA-PKcs expression by sub-chronically exposing normal liver L02 cells with 0.1 pM low dose of carcinogen TCDD (Fig. 1C ). c-Myc protein level as well as phosphorylation of Akt and GSK3 β is also increased in this cell model (Fig. 5C &5D) . Most importantly, re-silencing DNA-PKcs by siRNA strategy resulted in downregulated c-Myc (Fig. 1D) as well as decreased phosphorylation of Akt and GSK3 β (Fig. 5E ) in this cell model. Thus, it is conceivable that Akt and GSK3 β are involved in the mechanistic pathway by which DNAPKcs regulates c-Myc stability.
Conclusion
Given the facts that DNA-PKcs is a DNA damage sensing protein in responding to environmental genotoxic or oxidative stresses in cells and overexpression of DNA-PKcs frequently occurs in human cancers, long-term exposure of cells to genotoxins or oxidative stress, e.g. TCDD which produces oxidative stress in cells [48] , may lead to constitutive overexpression of DNA-PKcs as the consequence of persistently stressing reactions. We suggest that overexpressed DNA-PKcs is another critical cause contributing to the stabilization of c-Myc oncoprotein via the Akt/GSK3 β pathway. Taken 
